Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Placebo Controlled Study of the Safety & Efficacy of Therapeutic Treatment With AlloRx Stem Cells® in Patients With Pitt Hopkins Syndrome (Phase 1/2 Study)

NCT05165017 is registered in ClinicalTrials.gov with Vitro Biopharma Inc. as lead sponsor.

NCT NCT05165017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05165017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Placebo Controlled Study of the Safety & Efficacy of Therapeutic Treatment With AlloRx Stem Cells® in Patients With Pitt Hopkins Syndrome (Phase 1/2 Study)
Lead sponsor
Vitro Biopharma Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2021
Completion date
December 31, 2023
Enrollment
26 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pitt hopkins syndrome